Related Experiment Video
Updated: Sep 1, 2025
Quantified Assessment of Infant's Gross Motor Abilities Using a Multisensor Wearable
Published on: May 17, 2024
The Polish Version of the Alberta Infant Motor Scale: Cultural Adaptation and Validation
Małgorzata Eliks1,2, Anna Sowińska3, Ewa Gajewska1
1Chair and Clinic of the Developmental Neurology, Poznan University of Medical Sciences, Poznań, Poland.
Insights
The Polish version of the Alberta Infant Motor Scale (AIMS) is a reliable tool for assessing infant motor skills from birth to 18 months. This culturally adapted scale demonstrates high validity and reliability for clinical and research use in Poland.
Area of Science:
- Pediatrics
- Developmental Psychology
- Motor Development
Background:
- The Alberta Infant Motor Scale (AIMS) is a widely used diagnostic tool for assessing infant motor performance from birth to 18 months.
- Cultural adaptation and validation are crucial for applying international assessment tools in diverse populations.
Purpose of the Study:
- To culturally adapt and validate a Polish version of the Alberta Infant Motor Scale (AIMS) for infants aged 0-18 months.
- To evaluate the reliability and concurrent validity of the Polish AIMS.
Main Methods:
- 145 infants (0-18 months) were assessed using the Polish AIMS, divided into four age groups.
- Intrarater and interrater reliability were analyzed using Intraclass Correlation Coefficients (ICC).
- Concurrent validity was assessed by comparing the Polish AIMS with the Peabody Developmental Motor Scales-2 (PDMS-2) gross motor scale.
Main Results:
- High intrarater (total ICC=0.99) and interrater (total ICC=0.99) reliability were observed across all positions and age subgroups.
- Excellent concurrent validity was found, with significant Spearman correlations between the Polish AIMS and PDMS-2 gross motor scale (r=0.97 overall, r=0.79-0.85 in subgroups).
- Reliability coefficients for individual positions and subgroups were consistently high, indicating robust measurement properties.
Conclusions:
- The Polish version of the AIMS is a reliable and valid tool for assessing the motor development of infants aged 0-18 months in Poland.
- The culturally adapted Polish AIMS can be confidently used in clinical practice and scientific research.
- This validated tool will aid in the early identification of motor delays and support targeted interventions for Polish infants.
Abstract:
The Alberta Infant Motor Scale (AIMS) is a diagnostic tool for the assessment of the motor performance of infants from the time of birth, to the period of independent walking (0-18 months). This study aims to derive a Polish version of the AIMS through its cultural adaptation and validation. The study included 145 infants aged 0-18 months, who were divided into four further age groups: 0-3 months, 4-7 months, 8-11 months, and older than 12 months. The validation was based on an analysis of intrarater and interrater reliability values, as well as concurrent validity, using the gross motor scale of Peabody Developmental Motor Scales-2 (PDMS-2). The total Intraclass Correlation Coefficient (ICC) for intrarater reliability was 0.99 (ICC range in positions was 0.87-0.99, in subgroups was 0.91-0.99), while in particular positions, the ICC ranges were as follows: prone 0.97-0.99, supine 0.94-0.99, sitting 0.95-0.99, and standing: 0.63-0.99. The total ICC for interrater reliability was 0.99 (ICC range in positions was 0.98-0.99, in subgroups was 0.91-0.99), while in particular positions, the ICC ranges were as follows: prone 0.95-0.99, supine 0.93-0.96, sitting 0.93-0.98, standing 0.91-0.98. Only the standing position was analyzed for the subgroup of participants over 12 months old. The Spearman correlation between the Polish version of the AIMS and the gross motor scale of PDMS-2 was significant in the total population (r = 0.97, p < 0.0001) and in subgroups (r = 0.79-0.85, p < 0.0001). The results of our study confirm that the Polish version of the AIMS is reliable for infants aged 0-18 months and can be applied to this population for clinical and scientific purposes.
Trial Registry:
ClinicalTrials.gov ID NCT05264064, URL https://clinicaltrials.gov/ ct2/show/NCT05264064.
